Objective: To quantitate insulin sensitivity in lean and obese non-diabetic baboons and examine the underlying cellular/molecular mechanisms responsible for impaired insulin action in order to characterize a baboon model of insulin resistance.
nsulin resistance is characterized by impaired response of target organs (e.g. skeletal muscle, liver, adipose tissue, heart) to the physiological effects of insulin and results in impaired glucose metabolism.
Insulin resistance is a characteristic feature of many common metabolic disorders including obesity, type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia as well as of the normal aging process, which collectively constitute risk factors for the development of atherosclerotic cardiovascular disease (1) (2) (3) .
Non-human primates occupy a unique place in biomedical and evolutionary research by virtue of their close genetic and physiological similarity to humans and represent a valuable model that has great relevance to the study of human disease. Old World monkeys, which recently (~25 millions years ago in evolutionary terms) diverged from the Hominoidea, have been most extensively studied (4, 5) . This taxonomic group includes vervet monkeys (Chlorocebus aethiops), rhesus macaques (Macaca mulatta), cynomolgus monkeys (Macaca fascicularis) and baboons (Papio hamadryas) (6) . Despite their relevance to human disease, there has been a shortage of primates available for biomedical research (7) . Baboons and humans share great genetic similarity, with ~96% homology evident at the DNA level (8) . The sequences of specific genes and the arrangements of genetic loci on chromosomes reflect the close evolutionary relationship between these two species (9) . Not surprisingly, nonhuman primates develop many diseases similar to those in man and they have been used as a model for osteoporosis, lipoprotein and atherosclerosis research (10) (11) (12) , and most recently to study the genetics of obesity (4, 13) .
Baboons are long-lived animals with an average lifespan of ~25 years. They can be maintained for generations in controlled conditions, thus providing a valuable model for studying interactions between inherited, constitutional, and environmental factors such as diet and exercise (12, 14, and 15) . There are no established glycemic cut points for the diagnosis of diabetes in the baboon. Nonetheless, the development of overt T2DM is well documented (16) (17) (18) , although the exact incidence remains to be determined. The natural history of T2DM in baboons is likely to parallel the natural history that has been observed in other primates (6, 19 , and 20) and in humans (1) . Thus, as baboons gain excessive weight, they become insulin resistant and glucose intolerant. Therefore, we sought to quantitate insulin sensitivity in a population of non-diabetic baboons using the hyperinsulinemic euglycemic clamp to characterize the clinical and biochemical characteristics of insulin resistant baboons and to examine the underlying cellular/molecular mechanisms responsible for the impairment in insulin action.
METHODS

Study Population.
Twenty non-diabetic baboons (10 males, 10 females) randomly selected from the Southwest National Primate Research Center at Southwest Foundation for Biomedical Research, San Antonio, Texas were studied. As part of the initial evaluation, baseline anthropometric measurements and biochemical profiles, including fasting plasma glucose (FPG) Insulin sensitivity was assessed with the euglycemic insulin clamp technique as previously described (21). After an overnight fast (~12 hours) each baboon was sedated with ketamine hydrochloride (10 mg/kg IM) before arrival in the procedure room. Endotracheal intubation was performed using disposable cuffed tubes (6.5-8.0 mm diameter) under direct laryngoscopic visualization, and all the animals were supported with FiO 2 98-99.5% by a pressure controlled ventilator adjusted, as necessary, to keep the oxygen saturation above 95%. The maintenance of anesthesia consisted of an inhaled isofluorane (0.5-1.5%) and oxygen mix. Catheters were inserted into the femoral vein for insulin and glucose infusion and into the contralateral femoral artery for blood sampling. Fasting plasma glucose (FPG), free fatty acid (FFA), and insulin concentrations were measured at -10 and 0 minutes. At t = 0 min, a primedcontinuous infusion of human regular insulin (Novolin; Novo Nordisk, Princeton, NJ) was started and continued at 60 mU/m 2 body surface area (BSA) per minute for 120 min. BSA was estimated from the body mass (M) by the Meeh formula: A = K.M 2/3 , in which the constant K = 12.65, as proposed by Van As and Lombard for the baboon (22). After the start of insulin, plasma glucose was measured every 5 minutes and the infusion of 20% glucose solution was adjusted, based on the negative feedback principle, to maintain the plasma glucose concentration at the desired level of ~90 mg/dl.
Plasma insulin and FFA concentrations were measured at 30, 60, and 90, 100, 110, and 120 minutes. We made a conservative approach adjusting the coefficient of determination (R 2 ) by the number of explanatory variables. This approach provides the explained percent of variance after the contribution of chance is subtracted. The coefficients were standardized to judge relative predictive power of independent variables and partial correlations were calculated to remove the overlap effect between variables.
Finally, mean adjusted predictions were calculated for Rd using the significant regression equations.
RESULTS
Characteristics of the study population are summarized in Table 1 Figure 3C ). Maximal stimulation of AS160 phosphorylation occurred at 120 min in both IS (P<0.001) and IR (P<0.05) groups with a modest, non-significant reduction of AS160 phosphorylation in IR at 120 min as compared to IS baboons ( Figure  3D ).
In contrast to skeletal muscle, in visceral fat of IS baboons, maximal stimulation of IRS-1 tyrosine phosphorylation occurred at 120 min and it was significantly different compared to the IR group (P<0.05; Figure 4A ). There was a non-significant trend for an increase in the association of P85 to IRS-1 in the IS baboon group at 120 min ( Figure 4B ). In the IS baboons Akt phosphorylation was maximally stimulated at 120 min (P<0.001) and this response was significantly lower in the IR group (P<0.05; Figure 4C ). In fat from IS baboons AS160 phosphorylation was maximal at 120 min and it was significantly lower in the IR group (P<0.05; Figure 4D ).
In the basal state, GLUT1 content in muscle was similar between groups and there was a non-statistically significant trend for lower Glut-4 muscle content in the IR baboons (P=0.18) ( Figure 5A-B ). There were no significant differences in Akt and AS160 muscle content between groups ( Figure 5C and 5D). In adipose tissue, there was no change in GLUT-4 content between groups. However, we found a non significant decrease in Akt content. Collectively, these results demonstrate that IR baboons have major insulin signaling defects in both muscle and fat. Gene and Protein Sequences Similarities. The primer sequences are shown as Supplement Figure 1 (A-J). The obtained baboon cDNA sequences had a high degree of identity with the reported human sequences for the analyzed genes. This similarity allows the use of human reagents to study baboon tissues and circulating products (29-31).
We sequenced 73% of the coding region of insulin. This fragment was 95% identical to the human cDNA and 96% to the protein and contains the characteristic insulin-family structure (supplement Fig  2A) .
We sequenced 100% of the coding region of the insulin receptor (INSR). The sequence is 97% identical to the human cDNA and amino acid sequence (supplement Fig 2B) . The bioinformatics analyses of the sequence identified numerous functional domains including tyrosine kinase catalytic domains, serine/threonine protein kinase catalytic domains, P-kinase domains and receptor L domains and furin-like repeats with cysteine rich regions. The exact function of these domains is not known. Furin is a serine-kinase dependent proprotein processor.
The coding sequence for baboon insulin receptor substrate 1 (IRS-1) was 97% identical to human cDNA and 98% identical at the protein level (supplement Fig 2C) . Baboon IRS-1 contains a phosphotyrosine binding site and a plekstrin homology domain, characteristic of molecules involved in cell signaling process. Identified functional sites for phosphorylation and other functional sites in the predicted amino acid sequence were found. A deletion of two amino acids was observed in positions 686 and 687 of baboon IRS-1. An insertion of 11 glutamines in positions 881to 891 and an arginine residue in position 1231 also were found. No identified functional sites are located within these regions. However, the possible functional effects of these differences remain to be elucidated.
Supplement Fig 2D shows the alignment of the human baboon protein sequences for PI 3-Kinase. The present sequence covered 95% of the reported human sequence and was 98% identical to the human cDNA and 99% to the protein. The alignments of the baboon and human sequence for P85 are shown in supplement Fig 2E. This represents 75% of the human sequence. The percentage of identity between the cDNA is 98% and 99% for amino acid sequences.
In supplement Fig 2F the comparison between the human and baboon AKT-1 is shown. We sequenced 85% of the reported amino acid sequence. This product is 97% identical to the human cDNA and 99% to the human protein.
The baboon sequence contains an AKT putative phosphoinositide binding site, a serine/threonine protein kinase catalytic domain and an Akt pleckstrin homology (PH) domain. AKT-2 was 99% identical to the human protein (supplement Fig 2G) . For the AS160 subunit, the sequences were 97% and 98% identical to reported human cDNA and protein, respectively (supplement Fig 2H) . The baboon sequence for AS160 showed the Pollux phosphotyrosine-binding domain that characterizes this family of molecules across different species. The TBC domain was found as well, indicating GTP activator activity. Finally GLUT-1 and 4 were 99% identical to the reported amino acid human sequence (supplement Fig I and J) Overall, these baboon genes exhibited highly conserved sequences and functional domains when compared with the reported human proteins.
Transmission Electron Microscopy.
Quantitative analysis showed no differences between insulin sensitive and insulin resistant baboons in total area occupied by mitochondria (7.5 ± 4 vs. 7. 
DISCUSSION
In this study, we describe a new nonhuman primate model for the study of insulin resistance. Previous studies have demonstrated that rhesus monkeys (Macaca mulatta) become insulin resistant and develop diabetes as they age and become obese (15, 19) . The present results, as well as those in monkeys, demonstrate that non-human primates share many physiologic and pathophysiologic similarities with humans. We also demonstrate that insulin, insulin receptor, IRS1, PI 3 kinase, AS160 and AKT are 97-98% similar to human proteins. Although insulin resistance has been demonstrated with the hyperinsulinemic euglycemic clamp in rhesus monkeys (32, 33), the present study represents the first description of insulin resistance and its association with increased adiposity using the insulin clamp technique in baboons. Previous work has addressed conditions and markers associated with insulin resistance such as atherosclerosis, dyslipidemia and obesity in this model (4, 12, 27 , and 28). Kemnitz et al (34) reported that baboons living near tourist facilities in Africa with easy access to calorically dense food had a three-fold elevation in fasting plasma insulin, as well as increased body mass and higher levels of total cholesterol, VLDL and LDL cholesterol compared to those who consumed only forage and maintained regular physical activity. These observations emphasize the deleterious metabolic effects induced in this primate by changes in lifestyle. Although we did not examine individual patterns of food intake and exercise, it is likely that the change from the wild to captivity explains the development of obesity and insulin resistance in baboons in the present study.
Moreover, we demonstrate that the molecular mechanisms involved in muscle and adipose insulin resistance are similar to those observed in man (35-37) and in other murine models (23,24,38,39). While Akt and AS160 phosphorylation have been found to be normal in muscle of insulin-resistant non-obese first degree relatives of subjects with T2DM (40) in human obesity and T2DM the ability of insulin to stimulate IRS-1 tyrosine phosphorylation, increase the association of p85 with IRS-1 and activate P-Akt and P-AS160 are markedly impaired (41-43). Interestingly we find that insulinstimulated muscle IRS-1 tyrosine phosphorylation and p85 associated with IRS-1 is maximal at 30 minutes and dissipates by 120 minutes. In contrast, we demonstrate that muscle P-Akt and P-AS160 activation continue to increase from 30 to 120 minutes during the insulin clamp in insulin sensitive baboons. Insulin's effect on insulin signaling in visceral fat of insulin sensitive baboons differs markedly from that in muscle ( Figure 4 ). In insulin resistant baboons the ability of insulin to cause IRS-1 tyrosine phosphorylation and to activate PI-3 kinase and distal signaling molecules (P-Akt) is markedly impaired in both muscle and fat tissue. These findings are in general agreement with the above mentioned studies (41-43), although we cannot exclude the possibility that also other signaling molecules, besides Akt might play a role to explain the observed differences between species. As observed in humans, some baboons become obese even though they have been exposed to the same amount and quality of food and have unrestricted physical activity (although probably less than in the wild), providing support for an inherited metabolic constitution and susceptibility to overweight and development of insulin resistance (4,44). The long lifespan of the baboon and the ability to examine gene-environment interactions makes this animal an interesting model to examine the effect and long term impact of interventional therapies aimed to treat or prevent insulin resistance, obesity, and T2DM. Although the primary aim of the present study was to quantitate insulin-mediated glucose disposal and insulin signaling, we estimated HOMA-β as a surrogate marker of beta cell function. Consistent with studies in morbidly obese patients (45), we observed an inverse correlation between HOMA-β and HOMA-IR, BMI, and percent body fat. Of note, and consistent to what has been shown in other primates, the baboon also develops islet amyloidosis and overt diabetes (17, 18) , similar to that in humans with T2DM (46, 47). Since baboons will not ingest a glucose load, performance of an oral glucose tolerance test is not a feasible option in this primate to estimate insulin secretion.
Although our results demonstrate a significant sexual dimorphism with respect to some plasma lipid (FFA, triglyceride, LDL cholesterol) levels, the insulin-stimulated glucose disposal rate (marker of insulin resistance) is not affected by gender, and in both males and females the severity of whole body insulin resistance is similarly related to the increase in abdominal adiposity. Since waist circumference correlated highly with both % body fat and BMI, the use of anthropometric measurements provides a simple mean to identify IR baboons. Since the fasting plasma insulin concentration (and consequently HOMA-IR) demonstrates a marked gender dimorphism in our baboon population, these indices do not represent good surrogate markers of insulin resistance. HOMA-IR is determined by the product of the FPG and FPI concentrations. Since the FPG concentration is primarily determined by the rate of hepatic glucose production and insulin is the major regulator of HGP, HOMA-IR primarily reflects hepatic insulin resistance (48). The 70% lower value for HOMA-IR in females compared to males suggests the presence of significant hepatic resistance that is related to female gender. Since the dose response curve relating the plasma insulin concentration to suppression of HGP is markedly left-ward shifted with respect to muscle (49), insulin clamp studies carried out with lower insulin infusion rates and in combination with tritiated glucose are needed to further characterize the hepatic insulin resistance.
In conclusion, the results of the present study support the use of the baboon as a pertinent non-human primate model to study the underlying cellular/molecular mechanisms responsible for insulin resistance, as well as to examine pharmacologic interventions to reverse it.
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SUPPLEMENTARY METHODS
Immunoprecipitation and Western Blotting. Muscle and fat samples were weighed while still frozen and homogenized in ice-cold lysis buffer (containing 20 mmol/l Tris [pH 7.5], 10 mmol/l sodium pyrophosphate, 100 mmol/l sodium fluoride, 2 mmol/l sodium orthovanadate, 5 mmol/l EDTA (pH 8.0), 1% Nonidet P-40, 1 mmol/l PMSF, 3 mmol/l benzamidine, 10 µg/ml leupeptin, and 10 µg/ml aprotinin). Homogenates were rotated for 1 h at 4°C and then centrifuged at 14,000 g for 10 min at 4°C. The supernatants were collected and protein concentrations measured by Bradford assay. Insulin receptor tyrosine phosphorylation was determined by antiphosphotyrosine immunoblot analysis of anti-insulin receptor immunoprecipitates of lysates. Anti-IRS-1 antibody (Upstate Biotechnology, NY) and protein A sepharose beads were used for immunoprecipitation of IRS-l-associated PI 3-kinase. Lysate proteins were separated by 8% SDS-PAGE and transferred to nitrocellulose membranes. After blocking in Tris-buffered saline with 5% bovine serum albumin or 5% nonfat dry milk, membranes were incubated overnight at 4°C with the primary antibody against phospho-tyrosine (PY 99; Santa Cruz Biotechnology, CA), anti-PI3 kinase (P85; Upstate Biotechnology), phospho-Akt (Ser 473 ; Cell Signaling, MA), and phospho-AS160 (Cell Signaling, MA). Bound antibodies were detected with anti-rabbit immunoglobulin-horseradish peroxidase-linked whole antibody and by using enhanced chemiluminescent reagents (PerkinElmer Life Science, MA). Membranes were exposed to film, and band intensity was quantified using Image Tool Software (UTHSCSA). Cloning and sequencing of baboon insulin signaling molecules. Total RNA was isolated from baboon adipose tissue, pancreas and skeletal muscle samples using TRI-REAGENT (Molecular Research Center, Inc, Cincinnati, OH, USA). All RNA samples were digested with RQ1 DNAse (Promega, Madison, WI) to eliminate traces of DNA, and checked for integrity in a 1% agarose gel stained with ethidium bromide.
Partial cDNA clones were obtained for: baboon insulin (INS), insulin receptor (INSR), insulin receptor substrate 1 (IRS-1); phosphoinositide-3-kinase, regulatory subunit, polypeptide 1, isoform 2 (p85); phosphoinositide-3-kinase, class 3 (PI 3-Kinase); v-akt murine thymoma viral oncogene homolog 1(AKT-1); AKT-2, AS160, glucose transporters-1 (GLUT-1) and 4 (GLUT-4), via two step reverse transcription followed by polymerase chain reaction (RT-PCR) method. Reverse transcription of single stranded DNA was done with MMLV reverse transcriptase by Ambion (Austin, TX) using 1 g of total RNA, 300 ng/reaction of random primers (hexamers) by Invitrogen (Carlsbad, CA). Primers were designed to cover the available cds human sequence for each gene using the Primers 3.0 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). All polymerase chain reactions were performed under the following conditions: 94° C for 5 minutes followed by 40 cycles of 94° C x 45 min, 55° C x 45 min and elongation step of 72° C x 45 min. A final elongation step of 72° C for 10 min was conducted.
The sequences used for primers design were as follows: INS (GI: 4557670), INSR (GI: 4557883), IRS-1 (GI: 5031804), PI 3-Kinase (GI: 21542569), P85α(GI: 32455252), AKT-1 (GI: 62241014), AKT2 (GI: 62241011), AS160 (GI: 7662197), GLUT-1 (GI: 62087554) and GLUT-4 (GI: 119610632). Amplification of cDNA was conducted by PCR using 3 μl of the reverse transcription reaction. PCR reactions were analyzed in a 3100 DNA analyzer (Applied Biosystems, Foster City, CA). The obtained data were aligned using the Sequencer v 4.0 software and compared with the human sequence in BLAST (www.ncbi.nlm.nih.gov/blast). The sequences were translated into amino acids for analyses of functional domains. A. Comparison between human (Homo sapiens) GI:4557670 and baboon (Papio hamadryas) insulin amino acid sequence.
A. Insulin (INS):
P hamadryas -------------LALWGPDPAPAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAED 37 H sapiens MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAED 60 ********* ************************************* P hamadryas PQVGQVELGGGPGPGSLQPLALEGSLQKRGIVEQCCTSICYLYQLENYC--81 H sapiens LQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCNL 111 ************* ************************** ********
B.
Comparison between human (Homo sapiens) GI:4557883 and baboon (Papio hamadryas) Insulin Receptor amino acid sequence P hamadryas MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL 60 H sapiens MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL 60 ************************************************************ P hamadryas QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL 120 H sapiens QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL 120 ************************************************************ P hamadryas VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSPILDSVEDNLIVLNKDHNE 180 H sapiens VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE 180 ***************************************** ******** ****** ** P hamadryas ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL 240 H sapiens ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL 240 ************************************************************ P hamadryas GNCSEPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG 300 H sapiens GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG 300 **** ******************************************************* P hamadryas CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC H sapiens CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC 360 ************************************************************ P hamadryas TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL 420 H sapiens TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL 420 ************************************************************ P hamadryas EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE 480 H sapiens EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE 480 ************************************************************ P hamadryas RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ 540 H sapiens RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ 540 ************************************************************ P hamadryas NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS 600 H sapiens NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS 600 ************************************************************ P hamadryas DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQDILKWKPPSDPNGNITRYLVFWE 660 H sapiens DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE 660 ************************************* *************** ****** P hamadryas RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL 720 H sapiens RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL 720 ************************************************************ P hamadryas KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF 780 H sapiens KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF 780 ************************************************************ P hamadryas PNTSSTSMPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV 840 H sapiens PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV 840 ******* **************************************************** P hamadryas SARTMPEAKADDIVGPVTHEIFENNLVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV 900 H sapiens SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV 900 ************************* ********************************** P hamadryas SRKHFALERGCRLRGLSPGNYSVRVRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG 960 H sapiens SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG 960 ************************ *********************************** P hamadryas PLIFVFLFSIVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVPR 1020 H sapiens PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR 1020 ********* ************************************************ * P hamadryas EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG 1080 H sapiens EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG 1080 ************************************************************ P hamadryas FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA 1140 H sapiens FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA 1140 ************************************************************ P hamadryas AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV 1200 H sapiens AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV 1200 ************************************************************ P hamadryas RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN 1260 H sapiens RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN 1260 ************************************************************ P hamadryas CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME 1320 H sapiens CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME 1320 ************************************************************ P hamadryas FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN 1380 H sapiens FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN 1380 ************************************************************ P hamadryas PS 1382 H sapiens PS 1382 **
C.
Comparison between human (Homo sapiens) GI:5031804 and baboon (Papio hamadryas) insulin receptor substrate 1 (IRS-1) amino acid sequence.
P hamadryas MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAP 60 H sapiens
MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAP 60 ************************************************************* P hamadryas KRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGH 120 H sapiens KRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGH 120 ************************************************************ P hamadryas HDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLI 180 H sapiens HDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLI 180 ************************************************************ P hamadryas GIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQV 240 H sapiens GIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQV 240 ************************************************************ P hamadryas DDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLT 300 H sapiens DDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLT 300 ************************************************************ P hamadryas RRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHR 360 H sapiens RRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHR 360 ************************************************************ P hamadryas GSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSP 420 H sapiens GSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSP 420 ************************************************************ P hamadryas SDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPN 480 H sapiens SDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPN 480 ************************************************************ P hamadryas GHYILSRGGNGHRYTPGTGLGTSPALAGDEASSAADLDNRFRKRTHSAGTSPTITHQKTP 540 H sapiens GHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTP 540 ************* ***************** **************************** P hamadryas SQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTHSYPEEGLEMHPLERRGGHHR 600 H sapiens SQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHR 600 *************************************** ******************** P hamadryas PDSSTLHTDDGYMPMSPGVAPVPSSRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPN 660 H sapiens PDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPN 660 ************************ *********************************** P hamadryas GYMMMSPSGGCSPDIGGGPSSSSSS//AVPSGSSYGKLWTNGVGGHHSHVLPHPKPPVES 718 H sapiens GYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVES 720 ************************* ***** *************************** P hamadryas SGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEP 778 H sapiens SGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEP 780 ************************************************************ P hamadryas EEGARHQHLRLSASSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPH 838 H sapiens EEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPH 840 ************ ********** ************************************ P hamadryas LPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQQQQQQQQQQQQPLLHPPE 898 H sapiens LPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQ///////////PLLHPPE 889 ****************************************** ******* P hamadryas PKSPGEYVNIEFGSDQPGYLSGPVASRSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPG 958 H sapiens PKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPG 949 **************** ******** ********************************* P hamadryas RRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPIAP 1018 H sapiens RRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAP 1009 ********************************************************* ** P hamadryas VSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGM 1078 H sapiens VSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGM 1069 ************************************************************ P hamadryas SAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAIGGGG 1138 H sapiens SAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGG 1129 ******************************************************* **** P hamadryas GSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAQLCGAAGGLENGLNYIDLDLVKDFK 1198 H sapiens GSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFK 1189 *********************************** ************************ P hamadryas QRPQECSPHPQPPPPPPPHQPLGSSESSSTRRRSSEDLSAYASISFQKQPEDLQ 1252 H sapiens QCPQECTPEPQPPPPPPPHQPLGSGESSSTRR/SSEDLSAYASISFQKQPEDRQ 1242 * **** * *************** ******* ******************* *
D.
Comparison between human (Homo sapiens) GI: 21542569 and baboon (Papio hamadryas) phosphoinositide-3-kinase, class 3 (PI 3-Kinase)
H sapiens PVGGTTVSLFGKYGMFRQGMHDLKVWPNVEADGSEPTKTPGRTSSTLSEDQMSRLAKLTK 180 P hamadryas ---------------------DLKVWPNVEADGSEPTKTPGRTSSTLSEDQMSRLAKLTK 39 *************************************** H sapiens AHRQGHMVKVDWLDRLTFREIEMINESEKRSSNFMYLMVEFRCVKCDDKEYGIVYYEKDG 240 P hamadrya AHRQGHMVKVDWLDRLTFREIEMIE-SEKRSSNFMYLMVEFRCVKCDDKEYGIVYYEKDG 98 ************************ /********************************** H sapien DESSPILTSFELVKVPDPQMSMENLVESKHHKLARSLRSGPSDHDLKPNAATRDQLNIIV 300 P hamadryas DESSPILTSFELVKVPDPQMSMENLVESKHHKLARSLRSGPSDHDLKPNAATRDQLNIIV 158 ************************************************************ H sapiens SYPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALELLGKWKPMDV 360 P hamadryas SYPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALELLGKWKPMDV 218 ************************************************************ H sapiens EDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQALKYENFDDIKNGLEPTKK 420 P hamadrya EDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQALKYENFDDIKNGLEPTKK 278 ************************************************************ H sapiens DSQSSVSENVSNSGINSAEIDSSQIITSPLPSVSSPPPASKTKEVPDGENLEQDLCTFLI 480 P hamadryas DSQSSVSENVSNSGINSAEIDSSQIITSPLPSVSSPPPASKTKEVPDGENLEQDLCTFLI 338 ************************************************************ H sapiens SRACKNSTLANYLYWYVIVECEDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRS 540 P hamadryas SRACKNSTLANYLYWYVIVECEDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRS 398 ************************************************************ H sapiens LLAAQQTFVDRLVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVK 600 P hamadryas LLAAQQTFVDRLVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVK 458 ************************************************************ H sapiens IRGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQIISLMDKLLRK 660 P hamadryas IRGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQIISLMDKLLRK 518 ************************************************************ H sapiens ENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQNFFRKYAPSENGPNGISAE 720 P hamadryas ENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQNFFRKYAPSENGPNGISAE 578 ************************************************************ H sapiens VMDTYVKSCAGYCVITYILGVGDRHLDNLLLTKTGKLFHIDFGYILGRDPKPLPPPMKLN 780 P hamadryas VMDTYVKSCAGYCVITYILGVGDRHLDNLLLTKTGKLFHIDFGYILGRDPKPLPPPMKLN 638 ************************************************************ H sapiens KEMVEGMGGTQSEQYQEFRKQCYTAFLHLRRYSNLILNLFSLMVDANIPDIALEPDKTVK 840 P hamadryas KEMVEGMGGTQSEQYQEFRKQCYTA-----------------------------------653 ************************* H sapiens KVQDKFRLDLSDEEAVHYMQSLIDESVHALFAAVVEQIHKFAQYWRK 887
Comparison between human (Homo sapiens) GI: 32455252 and baboon (Papio hamadryas) phosphoinositide-3-kinase, regulatory subunit, polypeptide 1, isoform 2 (P85 ) sequence.
AEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKY 120 *********************** P hamadryas GFSDPLTFNSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLH 83 H sapiens GFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLH 180 ******** *************************************************** P hamadryas EYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIE 143 H sapiens EYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIE 240 ************************************************************ P hamadryas KFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDL 203 H sapiens KFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDL 300 ************************************************************ P hamadryas IQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSN 263 H sapiens IQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSN 360 ************************************************************ P hamadryas RNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSS 303 H sapiens RNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSS 420 ************************************************************ P hamadryas LKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR 337 H sapiens LKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR 454 **********************************
F.
Comparison between human (Homo sapiens) GI: 62241011 and baboon (Papio hamadryas) v-akt murine thymoma viral oncogene homolog 1 (AKT-1) sequence.
P hamadryas ---------------RCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKHEEEMMDF 45 H sapiens QLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDF 120 ************************************* *** *** P hamadryas RSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKI 105 H sapiens RSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKI 180 ************************************************************ P hamadryas LKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLS 165 H sapiens LKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLS 240 ************************************************************ P hamadryas RERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGI 225 H sapiens RERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGI 300 ************************************************************ P hamadryas KDGATMKTFCGTPEYLAPZVLEDNDYXRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFEL 285 H sapiens KDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFEL 360 ****************** ******* ********************************* P hamadryas ILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKK 345 H sapiens ILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKK 420 ************************************************************ P hamadryas LSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA 405 H sapiens LSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA 480 ************************************************************
G.
Comparison between the AKT-2 predicted amino acid sequence of Papio hamadryas and Homo sapiens (GI: 119577345).
P hamadryas ERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEW 60 H sapiens
ERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEW 60 ************************************************************ P hamadryas MRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSAAEEMEVAVSKARAKVTMNDFDYLKLLG 120 H sapiens MRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLG 120 ******************************** ************************** P hamadryas KGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAF 180 H sapiens KGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAF 180 ************************************************************ P hamadryas QTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLE 240 H sapiens QTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLE 240 ************************************************************ P hamadryas NLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVV 300 H sapiens NLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVV 300 ************************************************************ P hamadryas MYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSD 360 H sapiens MYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSD 360 ************************************************************ P hamadryas AKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSL 420 H sapiens AKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSL 420 ************************************************************ P hamadryas GLLELDQRTHFPQFSYSASIRE 442 H sapiens GLLELDQRTHFPQFSYSASIRE 442 **********************
H.
Comparison between human (Homo sapiens) GI: 7662197 and baboon (Papio hamadryas) AS160 amino acid sequence.
P hamadryas ------------------------------------------------------------H sapiens
MEPPSCIQDEPFPHPLEPEPGVSAQPGPGKPSDKRFRLWYVGGSCLDHRTTLPMLPWLMA 60 P hamadryas ------------------------------------------------------------H sapiens EIRRRSQKPEAGGCGAPAAREVILVLSAPFLRCVPAPGAGASGGTSPSATQPNPAVFIFE 120
P hamadryas ---------HNSHDLTYFAYLIKAQPDDPESQMACHVFRATDPSQVPDVISSIRQLSKA H sapiens HKAQHISRFIHNSHDLTYFAYLIKAQPDDPESQMACHVFRATDPSQVPDVISSIRQLSKA 180 ************************************************** P hamadryas AMKEDAKPSKDNEDAFYNSQKFEVLYCGKVTVTHKKAPSSLIDDCMEKFSLHEQQRLKIQ H sapiens AMKEDAKPSKDNEDAFYNSQKFEVLYCGKVTVTHKKAPSSLIDDCMEKFSLHEQQRLKIQ 240 ************************************************************ P hamadryas GEQRSVDPGEDLADLEVVVPGSPGDCLPEEADGTDTHLGLPAVASQPALSSSRVCFPERI H sapiens GEQRGPDPGEDLADLEVVVPGSPGDCLPEEADGTDTHLGLPAGASQPALTSSRVCFPERI 300 **** ************************************ ****** ********** P hamadryas LEDSGFDEQQEFRSRCSSVTGVQRRVHEGSQKSQPRRRHASAPSHVQPSDSEKNRTMLFQ 128 H sapiens LEDSGFDEQQEFRSRCSSVTGVQRRVHEGSQKSQPRRRHASAPSHVQPSDSEKNRTMLFQ 360 ************************************************************ P hamadryas VGRFEINLISPDTKSVVLEKNFKDISSCSQGIKHVDHFGFICRESPEPGLSQYICYVFQC 188 H sapiens VGRFEINLISPDTKSVVLEKNFKDISSCSQGIKHVDHFGFICRESPEPGLSQYICYVFQC 420 ************************************************************ P hamadryas ASESLVDEVMLTLKQAFSTAAAPQSAKTQIKLCEACPMHSLHKLCERIEGLYPPRAKLV-247 H sapiens ASESLVDEVMLTLKQAFSTAAALQSAKTQIKLCEACPMHSLHKLCERIEGLYPPRAKLVI 480 ********************** ************************************ P hamadryas QRHLSSLTDNEQADIFERVQKMKPASDQEENELVILHLRQMCEAKQKTRRQHVHIGEGPC 307 H sapiens QRHLSSLTDNEQADIFERVQKMKPVSDQEENELVILHLRQLCEAKQKT///HVHIGEGPS 537 ************************ *************** ******* ******** P hamadryas TISNSTIPENATSSGRFKLDILKNKAKRSLTSSLENIFSRGANRMRGRLGSVDSFERSNS 367 H sapiens TISNSTIPENATSSGRFKLDILKNKAKRSLTSSLENIFSRGANRMRGRLGSVDSFERSNS 597 ************************************************************ P hamadryas LASEKDYSPGDSPPGTPPASPLSSAWQTFPEEDSDSPQFRRRAHTFSHPPSSTKRKLNLQ 427 H sapiens LASEKDYSPGDSPPGTPPASPPSSAWQTFPEEDSDSPQFRRRAHTFSHPPSSTKRKLNLQ 657 ********************* ************************************** P hamadryas DGRAQGVRSPLLRQSSSEQCSILSSVRRMCKESNSSSSLPSLHTSFSAPSFNAPCFLKSF 487 H sapiens DGRAQGVRSPLLRQSSSEQCSNLSSVRRMYKESNSSSSLPSLHTSFSAPSFTAPSFLKSF 717 ********************* ******* ********************* ** ***** P hamadryas YQNSGRLSPQYENEIRQDTASESSDGEGRKRTSSTCSNESLSVGGTSVTPRRISWRQRIF 495 H sapiens YQNSGRLSPQYENEIRQDTASESSDGEGRKRTSSTCSNESLSVGGTSVTPRRISWRQRIF 777 ************************************************************ P hamadryas LRVASPMNKSPSAMQQQDGLDRNELLPLSPLSPTMEEEPLVIFLSGEDDPEKIEERKKSK 517 H sapiens LRVASPMNKSPSAMQQQDGLDRNELLPLSPLSPTMEEEPLVVFLSGEDDPEKIEERKKSK 837 *****************************************:****************** P hamadryas ELRSLWRKAIHQQILLLRMEKENQKLEGASRDELQSRKVKLDYEEVGACQKEVLITWDKK 577 H sapiens ELRSLWRKAIHQQILLLRMEKENQKLE-ASRDELQSRKVKLDYEEVGACQKEVLITWDKK 896 *************************** ******************************** P hamadryas LLNCRAKIRCDMEDIHTLLKEGVPKSRRGEIWQFLALQYRLRHRLPNKQQPPDISYKELL 637 H sapiens LLNCRAKIRCDMEDIHTLLKEGVPKSRRGEIWQFLALQYRLRHRLPNKQQPPDISYKELL 956 ************************************************************ P hamadryas KQLTAQQHAILVDLGRTFPTHPYFSVQLGPGQLSLFNLLKAYSLLDKEVGYCQGISFVAG 697 H sapiens KQLTAQQHAILVDLGRTFPTHPYFSVQLGPGQLSLFNLLKAYSLLDKEVGYCQGISFVAG 1016 ************************************************************ P hamadryas VLLLHMSEEQAFEMLKFLMYDLGFRKQYRPDMMSLQIQMYQLSRLLHDYHRDLYNHLEEN 757 H sapiens VLLLHMSEEQAFEMLKFLMYDLGFRKQYRPDMMSLQIQMYQLSRLLHDYHRDLYNHLEEN 1076 ************************************************************ P hamadryas EISPSLYAAPWFLTLFASQFSLGFVARVFDIIFLQGTEVIFKVALSLLSSQETLIMECES 817 H sapiens EISPSLYAAPWFLTLFASQFSLGFVARVFDIIFLQGTEVIFKVALSLLSSQETLIMECES 1136 ************************************************************ P hamadryas FENIVEFLKSTLPDMNTSEMEKIITQVFEMDISKQLHAYEVEYHVLQDELQESSYSCEDS 877 H sapiens FENIVEFLKNTLPDMNTSEMEKIITQVFEMDISKQLHAYEVEYHVLQDELQESSYSCEDS 1196 ********* ************************************************** P hamadryas EPLEKLERANSQLKRQNMDLLEKLQVAHAKIQALESNLENFLTRETKMKSLIRTLEQEKM 937 H sapiens ETLEKLERANSQLKRQNMDLLEKLQVAHTKIQALESNLENLLTRETKMKSLIRTLEQEKM 1256 * ************************** *********** ******************* P hamadryas AYQKTVEQIRKLLPADALANCELLLRDLSCNPNNKAKIGSKP 979 H sapiens AYQKTVEQLRKLLPADALVNCDLLLRDLNCNPNNKAKIGNKP 1298 ******** ********* ** ****** ********** **
